Showing results (71-80 of 88) with videos related to
Sort By:
Pageof 9
Cell|July 9, 2019
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome PredictionDavid M Kurtz, Mohammad S Esfahani, Florian Scherer, et al.Blood|October 22, 2015
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trialKirsten Fischer, Jasmin Bahlo, Anna Maria Fink, et al.Leukemia|March 27, 2019
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemiaBilly Michael Chelliah Jebaraj, Eugen Tausch, Dan A Landau, et al.Haematologica|February 29, 2020
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trialPaula Cramer, Julia V Tresckow, Sandra Robrecht, et al.The Lancet. Oncology|May 25, 2016
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialBarbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, et al.Blood|June 26, 2023
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mutHenriette Huber, Eugen Tausch, Christof Schneider, et al.Leukemia|February 20, 2020
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trialCarmen D Herling, Florence Cymbalista, Carolin Groß-Ophoff-Müller, et al.Blood|December 25, 2009
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyChristiane Pott, Eva Hoster, Marie-Helene Delfau-Larue, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.Genes, Chromosomes & Cancer|November 3, 2019
Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemiaPaurnima Patil, Agata Cieslak, Stephan H Bernhart, et al.Pageof 9